NCT05279495 (CNXR-001D) is a NA clinical trial of In a double-blinded fashion, 250 mg CANNAXR cream in Photoaging, sponsored by MINO Labs, LLC.

Who is sponsoring NCT05279495?

NCT05279495 is sponsored by MINO Labs, LLC.

What drugs are being tested in NCT05279495?

Interventions in NCT05279495: In a double-blinded fashion, 250 mg CANNAXR cream, Topical VEHICLE cream.

What condition does NCT05279495 study?

NCT05279495 studies Photoaging.

Is NCT05279495 still recruiting?

NCT05279495 is currently completed. Last updated 8 May 2025.

Last reviewed 2025-05-08 · How we verify

NCT05279495: CNXR-001D

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers

Completed NA Last updated 8 May 2025

What this trial tests

NA trial testing In a double-blinded fashion, 250 mg CANNAXR cream in Photoaging in 20 participants. Completed in 15 May 2023.

Timeline

15 January 2023

Primary endpoint
1 April 2023

15 May 2023

Quick facts

Lead sponsor	MINO Labs, LLC
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	20
Start date	15 January 2023
Primary completion	1 April 2023
Estimated completion	15 May 2023
Sites	1 location across United States

Drugs / interventions tested

In a double-blinded fashion, 250 mg CANNAXR cream
Topical VEHICLE cream

Conditions studied

Photoaging — all drugs for Photoaging →

Sponsor

MINO Labs, LLC

Who can join

Adults 22 to 65, any sex, with Photoaging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ultraviolet light A (UVA) causes oxidization of guanine to mutagenic 8-Oxoguanine (8-OxoG) and the most frequent and best characterized mutation in mitochondrial DNA (mtDNA), a deletion of 4,977 base pairs, called the "common deletion", a marker of photoaging.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Topical nanoencapsulated cannabidiol cream as an innovative strategy combating UV-A-induced nuclear and mitochondrial DNA injury: A pilot randomized clinical study.
McCormick E, Han H, Abdel Azim S, Whiting C, et al · · 2024 · cited 8× · PMID 39025264 · DOI 10.1016/j.jaad.2024.06.088

Verify or expand the search:

Other recruiting trials for Photoaging

Currently open trials in the same condition.

NCT06029725 — RFMN in Combination With 1927 nm Thulium Laser for Treating Photoaged Skin · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05279495 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MINO Labs, LLC
Last refreshed: 8 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05279495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing